Related Experiment Video
Updated: May 12, 2026
Analysis of Zebrafish Larvae Skeletal Muscle Integrity with Evans Blue Dye
Published on: November 30, 2015
A Comparison of the 2022 Versus 2011 National Institute of Child Health and Human Development Web-Based Risk
Mitchell Kinkor1, Jake Schneider2, Farhath Sulthana3
1Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO.
Insights
The 2022 and 2011 National Institute of Child Health and Human Development estimators show similar accuracy in predicting infants needing steroid treatment for bronchopulmonary dysplasia (BPD). However, both have limited accuracy in predicting death or severe BPD.
Area of Science:
- Neonatal Medicine
- Respiratory Medicine
- Pediatric Critical Care
Background:
- Bronchopulmonary dysplasia (BPD) is a significant complication in preterm infants.
- Accurate identification of infants at high risk for BPD is crucial for timely intervention.
- The National Institute of Child Health and Human Development (NICHD) has developed estimators to predict BPD risk.
Purpose of the Study:
- To compare the predictive accuracy of the 2022 NICHD estimator versus the 2011 NICHD estimator.
- To evaluate the performance of these estimators in identifying infants at high risk for BPD.
Main Methods:
- A retrospective single-center study included infants born at ≤28 weeks' gestation.
- Demographic and respiratory support data were used to calculate BPD risk using both estimators.
- Predictive accuracy was assessed using c-statistics and area under the receiver operator characteristic curves (AUC).
- Outcomes included systemic steroid treatment for BPD and a composite of death or severe BPD.
Main Results:
- Both the 2022 and 2011 BPD estimators demonstrated good-to-excellent accuracy (c-statistics 0.77–0.89) for predicting steroid treatment.
- Predictive accuracy for steroid treatment was similar between the two estimators.
- Both estimators showed poor AUC for predicting death or highest severity of BPD, with the 2022 estimator having acceptable AUC (0.773) for this outcome on day 28 of life.
Conclusions:
- The 2022 and 2011 NICHD BPD estimators exhibit comparable good-to-excellent accuracy for predicting the need for steroid treatment.
- Both estimators have poor-to-fair accuracy in predicting the composite outcome of death or severe BPD at 36 weeks' postmenstrual age.
Objective:
To compare the predictive accuracy of the 2022 vs 2011 National Institute of Child Health and Human Development estimator for identifying infants at high risk for bronchopulmonary dysplasia (BPD).
Methods:
We conducted a single-center retrospective study of infants ≤28 weeks' gestation. Demographic and respiratory support data were used to calculate risk for BPD or death by the BPD estimators. Our outcomes of interest included (1) treatment with systemic steroids for BPD and (2) composite outcome of death or highest severity of BPD at 36 weeks' postmenstrual age. We used c-statistics and area under receiver operator characteristic curves (AUC) to compare accuracy of the BPD estimators.
Results:
A total of 159 infants (mean gestational age, 26 weeks; mean birth weight, 837 g) were included. Steroid treatment for BPD occurred in 61 infants. We found that predictive accuracy was similar for both 2022 and 2011 BPD estimators, with c-statistics ranging from 0.77 to 0.89, indicating good-to-excellent accuracy for predicting steroid treatment. Twenty-one infants had death or grade 3 BPD based on definitions used in the 2022 estimator, and 68 infants had death or severe BPD based on definitions used in the 2011 estimator. Overall, we found both BPD estimators had poor AUC for predicting infants at high risk for death or highest severity of BPD, with the exception of the 2022 estimator, which had an acceptable AUC of 0.773 on postnatal day of life 28.
Conclusions:
The 2022 and 2011 BPD estimators both demonstrate similar good-to-excellent accuracy for identifying infants at high risk for steroid treatment, but poor-to-fair accuracy for predicting death or highest severity of BPD at 36 weeks' postmenstrual age.
More Related Videos
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:29Drug Dosing: Infants and Children
01:12Relative Risk
01:12Hazard Ratio
For example, in a clinical trial evaluating a...